

# Matteo Bellone

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3634083/publications.pdf>

Version: 2024-02-01

115  
papers

4,273  
citations

109321

35  
h-index

123424

61  
g-index

127  
all docs

127  
docs citations

127  
times ranked

6281  
citing authors

#	ARTICLE	IF	CITATIONS
1	Modulation of Microenvironment Acidity Reverses Anergy in Human and Murine Tumor-Infiltrating T Lymphocytes. <i>Cancer Research</i> , 2012, 72, 2746-2756.	0.9	470
2	Melanoma Cells Present a MAGE-3 Epitope to CD4+ Cytotoxic T Cells in Association with Histocompatibility Leukocyte Antigen DR11. <i>Journal of Experimental Medicine</i> , 1999, 189, 871-876.	8.5	204
3	Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression. <i>Nature Communications</i> , 2018, 9, 4832.	12.8	144
4	Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis. <i>Science</i> , 2021, 374, 216-224.	12.6	135
5	Ways to Enhance Lymphocyte Trafficking into Tumors and Fitness of Tumor Infiltrating Lymphocytes. <i>Frontiers in Oncology</i> , 2013, 3, 231.	2.8	132
6	Targeting TNF- $\alpha$ to Neoangiogenic Vessels Enhances Lymphocyte Infiltration in Tumors and Increases the Therapeutic Potential of Immunotherapy. <i>Journal of Immunology</i> , 2012, 188, 2687-2694.	0.8	128
7	Relevance of the Tumor Antigen in the Validation of Three Vaccination Strategies for Melanoma. <i>Journal of Immunology</i> , 2000, 165, 2651-2656.	0.8	127
8	The acidity of the tumor microenvironment is a mechanism of immune escape that can be overcome by proton pump inhibitors. <i>Oncotarget</i> , 2013, 2, e22058.	4.6	121
9	Tenascin-C Protects Cancer Stem-like Cells from Immune Surveillance by Arresting T-cell Activation. <i>Cancer Research</i> , 2015, 75, 2095-2108.	0.9	112
10	Co-expression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response. <i>European Journal of Immunology</i> , 1995, 25, 1154-1162.	2.9	111
11	Myasthenia gravis: recognition of a human autoantigen at the molecular level. <i>Trends in Immunology</i> , 1993, 14, 363-368.	7.5	103
12	Rapamycin inhibits relapsing experimental autoimmune encephalomyelitis by both effector and regulatory T cells modulation. <i>Journal of Neuroimmunology</i> , 2010, 220, 52-63.	2.3	88
13	PD-L1 Expression and CD8+ T-cell Infiltrate are Associated with Clinical Progression in Patients with Node-positive Prostate Cancer. <i>European Urology Focus</i> , 2019, 5, 192-196.	3.1	81
14	Modulators of arginine metabolism support cancer immunosurveillance. <i>BMC Immunology</i> , 2009, 10, 1.	2.2	79
15	Peripheral T cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization. <i>European Journal of Immunology</i> , 2005, 35, 66-75.	2.9	78
16	Antisense transcription at the TRPM2 locus as a novel prognostic marker and therapeutic target in prostate cancer. <i>Oncogene</i> , 2015, 34, 2094-2102.	5.9	72
17	Long non-coding RNAs as novel therapeutic targets in cancer. <i>Pharmacological Research</i> , 2016, 110, 131-138.	7.1	71
18	Crucial Role for Interferon $\gamma$ in the Synergism between Tumor Vasculature-Targeted Tumor Necrosis Factor $\alpha$ (NGR-TNF) and Doxorubicin. <i>Cancer Research</i> , 2004, 64, 7150-7155.	0.9	66

#	ARTICLE	IF	CITATIONS
19	Critical impact of the kinetics of dendritic cells activation on the in vivo induction of tumor-specific T lymphocytes. <i>Cancer Research</i> , 2003, 63, 3688-94.	0.9	65
20	Much More Than IL-17A: Cytokines of the IL-17 Family Between Microbiota and Cancer. <i>Frontiers in Immunology</i> , 2020, 11, 565470.	4.8	63
21	Bimodal CD40/Fas-Dependent Crosstalk between iNKT Cells and Tumor-Associated Macrophages Impairs Prostate Cancer Progression. <i>Cell Reports</i> , 2018, 22, 3006-3020.	6.4	62
22	iNKT Cells Control Mouse Spontaneous Carcinoma Independently of Tumor-Specific Cytotoxic T Cells. <i>PLoS ONE</i> , 2010, 5, e8646.	2.5	61
23	Peripheral T-Cell Tolerance Associated with Prostate Cancer Is Independent from CD4+CD25+ Regulatory T Cells. <i>Cancer Research</i> , 2008, 68, 292-300.	0.9	59
24	Experimental myasthenia gravis in congenic mice. Sequence mapping and H-2 restriction of T helper epitopes on the I $\pm$ subunits of <i>Torpedo californica</i> and murine acetylcholine receptors. <i>European Journal of Immunology</i> , 1991, 21, 2303-2310.	2.9	57
25	Invariant NKT cells contribute to chronic lymphocytic leukemia surveillance and prognosis. <i>Blood</i> , 2017, 129, 3440-3451.	1.4	56
26	Heterogeneous effects of B7-1 and B7-2 in the induction of both protective and therapeutic anti-tumor immunity against different mouse tumors. <i>European Journal of Immunology</i> , 1996, 26, 1851-1859.	2.9	52
27	Pushing tumor cells towards a malignant phenotype: Stimuli from the microenvironment, intercellular communications and alternative roads. <i>International Journal of Cancer</i> , 2014, 135, 1265-1276.	5.1	51
28	Nitric Oxide Confers Therapeutic Activity to Dendritic Cells in a Mouse Model of Melanoma. <i>Cancer Research</i> , 2004, 64, 3767-3771.	0.9	48
29	Vasculature-targeted tumor necrosis factor $\alpha$ increases the therapeutic index of doxorubicin against prostate cancer. <i>Prostate</i> , 2008, 68, 1105-1115.	2.3	47
30	Approaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cells. <i>MAbs</i> , 2013, 5, 34-46.	5.2	46
31	Targeting vasculogenesis to prevent progression in multiple myeloma. <i>Leukemia</i> , 2016, 30, 1103-1115.	7.2	46
32	In vitro priming of cytotoxic T lymphocytes against poorly immunogenic epitopes by engineered antigen-presenting cells. <i>European Journal of Immunology</i> , 1994, 24, 2691-2698.	2.9	45
33	Targeting Tumor Vasculature with TNF Leads Effector T Cells to the Tumor and Enhances Therapeutic Efficacy of Immune Checkpoint Blockers in Combination with Adoptive Cell Therapy. <i>Clinical Cancer Research</i> , 2018, 24, 2171-2181.	7.0	40
34	Prostate cancer stem cells are targets of both innate and adaptive immunity and elicit tumor-specific immune responses. <i>Oncolmmunology</i> , 2013, 2, e24520.	4.6	38
35	Cellular microchimerism as a lifelong physiologic status in parous women: An immunologic basis for its amplification in patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2003, 48, 1109-1116.	6.7	37
36	Microbiota-Propelled T Helper 17 Cells in Inflammatory Diseases and Cancer. <i>Microbiology and Molecular Biology Reviews</i> , 2020, 84, .	6.6	37

#	ARTICLE	IF	CITATIONS
37	Iron Induces Cell Death and Strengthens the Efficacy of Antiandrogen Therapy in Prostate Cancer Models. <i>Clinical Cancer Research</i> , 2020, 26, 6387-6398.	7.0	36
38	Induction of T-cell memory by a dendritic cell vaccine: a computational model. <i>Bioinformatics</i> , 2014, 30, 1884-1891.	4.1	35
39	Interleukin-30/IL27p28 Shapes Prostate Cancer Stem-like Cell Behavior and Is Critical for Tumor Onset and Metastasis. <i>Cancer Research</i> , 2018, 78, 2654-2668.	0.9	35
40	Vascular targeting, chemotherapy and active immunotherapy: teaming up to attack cancer. <i>Trends in Immunology</i> , 2008, 29, 235-241.	6.8	32
41	ACE polymorphisms and COVID-19-related mortality in Europe. <i>Journal of Molecular Medicine</i> , 2020, 98, 1505-1509.	3.9	32
42	Mechanisms by which the I-ABM12 Mutation Influences Susceptibility to Experimental Myasthenia Gravis: a Study in Homozygous and Heterozygous Mice. <i>Scandinavian Journal of Immunology</i> , 1995, 42, 215-225.	2.7	31
43	Apoptosis, cross-presentation, and the fate of the antigen specific immune response. , 2000, 5, 307-314.		31
44	T Cells Redirected to a Minor Histocompatibility Antigen Instruct Intratumoral TNF $\alpha$ Expression and Empower Adoptive Cell Therapy for Solid Tumors. <i>Cancer Research</i> , 2017, 77, 658-671.	0.9	30
45	Constitutive expression of the heat shock protein 72 kDa in human melanoma cells. <i>Cancer Letters</i> , 1994, 85, 211-216.	7.2	29
46	Modulators of Arginine Metabolism Do Not Impact on Peripheral T-Cell Tolerance and Disease Progression in a Model of Spontaneous Prostate Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 1012-1023.	7.0	29
47	Immune Checkpoint-Mediated Interactions Between Cancer and Immune Cells in Prostate Adenocarcinoma and Melanoma. <i>Frontiers in Immunology</i> , 2018, 9, 1786.	4.8	29
48	Role of antigen-presenting cells in cross-priming of cytotoxic T lymphocytes by apoptotic cells. <i>Journal of Leukocyte Biology</i> , 1999, 66, 247-251.	3.3	28
49	Homotypic and Heterotypic Activation of the Notch Pathway in Multiple Myeloma—Enhanced Angiogenesis: A Novel Therapeutic Target?. <i>Neoplasia</i> , 2019, 21, 93-105.	5.3	28
50	Modifications of the mouse bone marrow microenvironment favor angiogenesis and correlate with disease progression from asymptomatic to symptomatic multiple myeloma. <i>Oncolmmunology</i> , 2015, 4, e1008850.	4.6	27
51	Human Melanoma Cells Transfected with the B7-2 Co-Stimulatory Molecule Induce Tumor-Specific CD8 <sup>+</sup> Cytotoxic T Lymphocytes <i>In Vitro</i> . <i>Human Gene Therapy</i> , 1998, 9, 1335-1344.	2.7	25
52	Critical role of indoleamine 2,3-dioxygenase in tumor resistance to repeated treatments with targeted IFN $\alpha$ . <i>Molecular Cancer Therapeutics</i> , 2008, 7, 3859-3866.	4.1	25
53	Concomitant Tumor and Minor Histocompatibility Antigen—Specific Immunity Initiate Rejection and Maintain Remission from Established Spontaneous Solid Tumors. <i>Cancer Research</i> , 2010, 70, 3505-3514.	0.9	25
54	Chromogranin A Is Preferentially Cleaved into Proangiogenic Peptides in the Bone Marrow of Multiple Myeloma Patients. <i>Cancer Research</i> , 2016, 76, 1781-1791.	0.9	24

#	ARTICLE	IF	CITATIONS
55	Thymoma associated with systemic lupus erythematosus and immunologic abnormalities. <i>Lupus</i> , 2000, 9, 151-154.	1.6	23
56	A pilot Phase I study combining peptide-based vaccination and NGR-hTNF vessel targeting therapy in metastatic melanoma. <i>Oncolmmunology</i> , 2014, 3, e963406.	4.6	23
57	Constitutive and acquired mechanisms of resistance to immune checkpoint blockade in human cancer. <i>Cytokine and Growth Factor Reviews</i> , 2017, 36, 17-24.	7.2	23
58	Cancer immunotherapy: synthetic and natural peptides in the balance. <i>Trends in Immunology</i> , 1999, 20, 457-462.	7.5	22
59	Prostate cancer, tumor immunity and a renewed sense of optimism in immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 453-468.	4.2	22
60	Galectin-3 in Prostate Cancer Stem-Like Cells Is Immunosuppressive and Drives Early Metastasis. <i>Frontiers in Immunology</i> , 2020, 11, 1820.	4.8	22
61	The Immunogenicity of Dendritic Cell-Based Vaccines Is Not Hampered by Doxorubicin and Melphalan Administration. <i>Journal of Immunology</i> , 2005, 174, 3317-3325.	0.8	21
62	Type 2 Cytotoxic T Lymphocytes Modulate the Activity of Dendritic Cells Toward Type 2 Immune Responses. <i>Journal of Immunology</i> , 2006, 177, 2131-2137.	0.8	21
63	Won't you come on in? How to favor lymphocyte infiltration in tumors. <i>Oncolmmunology</i> , 2012, 1, 986-988.	4.6	21
64	Boosting Interleukin-12 Antitumor Activity and Synergism with Immunotherapy by Targeted Delivery with isoDGR-Tagged Nanogold. <i>Small</i> , 2019, 15, e1903462.	10.0	21
65	Gene Signatures Distinguish Stage-Specific Prostate Cancer Stem Cells Isolated From Transgenic Adenocarcinoma of the Mouse Prostate Lesions and Predict the Malignancy of Human Tumors. <i>Stem Cells Translational Medicine</i> , 2013, 2, 678-689.	3.3	20
66	Preferential pairing of T and B cells for production of antibodies without covalent association of T and B epitopes. <i>European Journal of Immunology</i> , 1994, 24, 799-804.	2.9	19
67	Booster Vaccinations against Cancer Are Critical in Prophylactic but Detrimental in Therapeutic Settings. <i>Cancer Research</i> , 2013, 73, 3545-3554.	0.9	17
68	Molecular mimicry among human autoantigens. <i>Trends in Immunology</i> , 1991, 12, 46-47.	7.5	16
69	Vaccine-Instructed Intratumoral IFN- $\gamma$ Enables Regression of Autochthonous Mouse Prostate Cancer in Allogeneic T-Cell Transplantation. <i>Cancer Research</i> , 2013, 73, 4641-4652.	0.9	16
70	Molecular modification of idiotypes from B-cell lymphomas for expression in mature dendritic cells as a strategy to induce tumor-reactive CD4+ and CD8+ T-cell responses. <i>Blood</i> , 2005, 105, 3596-3604.	1.4	15
71	Apoptosis-dependent subversion of the T-lymphocyte epitope hierarchy in lymphoma cells. <i>Cancer Research</i> , 2002, 62, 1116-22.	0.9	14
72	CD4+ T cells sustain aggressive chronic lymphocytic leukemia in $\frac{1}{4}$ -TCL1 mice through a CD40L-independent mechanism. <i>Blood Advances</i> , 2021, 5, 2817-2828.	5.2	13

#	ARTICLE	IF	CITATIONS
73	Imatinib Spares cKit-Expressing Prostate Neuroendocrine Tumors, whereas Kills Seminal Vesicle Epithelial Stromal Tumors by Targeting PDGFR- $\beta$ . <i>Molecular Cancer Therapeutics</i> , 2017, 16, 365-375.	4.1	11
74	Targeting Interleukin(IL)-30/IL-27p28 signaling in cancer stem-like cells and host environment synergistically inhibits prostate cancer growth and improves survival. , 2019, 7, 201.		11
75	T helper function of CD4+ cells specific for defined epitopes on the acetylcholine receptor in congenic mouse strains. <i>Journal of Autoimmunity</i> , 1992, 5, 27-46.	6.5	10
76	The Insider: Impact of the Gut Microbiota on Cancer Immunity and Response to Therapies in Multiple Myeloma. <i>Frontiers in Immunology</i> , 2022, 13, 845422.	4.8	10
77	Clustering of B and T Epitopes Within Short Sequence Regions of the Nicotinic Acetylcholine Receptor. <i>Scandinavian Journal of Immunology</i> , 1995, 41, 135-140.	2.7	9
78	[18F](2S,4R)-4-Fluoroglutamine as a New Positron Emission Tomography Tracer in Myeloma. <i>Frontiers in Oncology</i> , 2021, 11, 760732.	2.8	9
79	Fatty is not that bad: feeding short-chain fatty acids to restrain autoimmunity. <i>Cellular and Molecular Immunology</i> , 2017, 14, 878-880.	10.5	8
80	Immunosuppression via Tenascin-C. <i>Oncoscience</i> , 2015, 2, 667-668.	2.2	7
81	Immunotherapy: natural versus synthetic peptides. <i>Trends in Immunology</i> , 1998, 19, 98.	7.5	6
82	Prolonged exposure of dendritic cells to maturation stimuli favors the induction of type-2 cytotoxic T $\alpha$ lymphocytes. <i>European Journal of Immunology</i> , 2006, 36, 3157-3166.	2.9	6
83	Concurrent Allorecognition Has a Limited Impact on Posttransplant Vaccination. <i>Journal of Immunology</i> , 2011, 186, 1361-1368.	0.8	6
84	Boosting anticancer vaccines. <i>Oncolimmunology</i> , 2013, 2, e25032.	4.6	6
85	Autoantibodies against a 72-kDa ductal cell membrane glycoprotein in a patient affected by Sjögren's syndrome and gastric MALT lymphoma. <i>Annals of Hematology</i> , 2002, 81, 597-602.	1.8	5
86	Characterization of preclinical models of prostate cancer using PET-based molecular imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 1245-1255.	6.4	5
87	Use of Synthetic Peptides and High Affinity Protein Ligands for Structural Studies of Central and Peripheral Nicotinic Receptors. , 1989, , 291-309.		5
88	Dendritic Cell Activation Kinetics and Cancer Immunotherapy. <i>Journal of Immunology</i> , 2004, 172, 2727.2-2728.	0.8	4
89	A novel expressed prostatic secretion (EPS)-urine metabolomic signature for the diagnosis of clinically significant prostate cancer. <i>Cancer Biology and Medicine</i> , 2021, 18, 604-615.	3.0	4
90	Anticancer innovative therapy congress: Highlights from the 10th anniversary edition. <i>Cytokine and Growth Factor Reviews</i> , 2021, 59, 1-8.	7.2	4

#	ARTICLE	IF	CITATIONS
91	Bone Marrow Mobilization Of Endothelial Progenitor Cells Represents An Early Pathogenic Event During Multiple Myeloma Progression. <i>Blood</i> , 2013, 122, 680-680.	1.4	4
92	Tumor-targeting vaccination instructs graft-vs.-tumor immune responses. <i>Onc Immunology</i> , 2013, 2, e25996.	4.6	3
93	Crosstalk Between Prostate Cancer Stem Cells and Immune Cells: Implications for Tumor Progression and Resistance to Immunotherapy. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2019, , 173-221.	0.1	3
94	Cimetidine Treatment in Hyper-IgM Hypogammaglobulinemia. <i>JAMA - Journal of the American Medical Association</i> , 1987, 258, 1892-1892.	7.4	1
95	Impairment of lymphocyte suppressive system in recent onset insulin-dependent diabetes mellitus. correlation with blood glucose and serum insulin levels. <i>Acta Diabetologica Latina</i> , 1989, 26, 257-263.	0.2	1
96	Vitamin D-binding protein-derived macrophage-activating factor, GcMAF, and prostate cancer. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 2377-2378.	4.2	1
97	Goals and objectives of the Italian Network for Tumor Biotherapy (NIBIT). <i>Cytokine and Growth Factor Reviews</i> , 2017, 36, 1-3.	7.2	1
98	Engineered APCs for tumor immunotherapy. <i>Trends in Immunology</i> , 1996, 17, 198.	7.5	0
99	“Cancer Bio-Immunotherapy in Siena” Eleventh Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 17-19, 2013. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 131-135.	4.2	0
100	EP-2053: In-vivo imaging of rat leukocytes redistribution after pelvic irradiation. <i>Radiotherapy and Oncology</i> , 2016, 119, S968-S969.	0.6	0
101	Abstract A83: Modifications of the bone marrow microenvironment in the transition from monoclonal gammopathy of undetermined significance to multiple myeloma in $V\kappa^*MYC$ mice.. , 2013, , .		0
102	Dual targeting by TCR-redirectioned T cells enables remission from autochthonous mouse prostate cancer.. <i>Frontiers in Immunology</i> , 0, 4, .	4.8	0
103	Modifications of the bone marrow microenvironment in the transition from monoclonal gammopathy of undetermined significance to multiple myeloma in $V\kappa^*MYC$ mice. <i>Frontiers in Immunology</i> , 0, 4, .	4.8	0
104	Abstract 2613: Prostate cancer stem/initiating cells are targets of both innate and adaptive immunity and elicit potent immune responses against autochthonous prostate tumors.. , 2013, , .		0
105	Autoimmunity Against the Nicotinic Acetylcholine Receptor and the Presynaptic Calcium Channel at the Neuromuscular Junction. <i>E&amp;M Endocrinology and Metabolism</i> , 1994, , 151-189.	0.1	0
106	Pre-clinical evaluation of immunotherapy: The case for prostate cancer and the TRAMP model. , 2014, , 173-188.		0
107	Early Trafficking of Bone Marrow Derived-Endothelial Progenitor Cells Promotes Multiple Myeloma Progression. <i>Blood</i> , 2014, 124, 4719-4719.	1.4	0
108	Angiogenesis Associated with Alterations of the Bone Marrow Microenvironment Predicts Multiple Myeloma Progression to Symptomatic Disease in Mice and Humans. <i>Blood</i> , 2014, 124, 5678-5678.	1.4	0

#	ARTICLE	IF	CITATIONS
109	PD11-12 Development and Validation of a Novel EPS-Metaboloomic Signature for the Diagnosis of Clinically Significant Prostate Cancer.. Journal of Urology, 2019, 201, .	0.4	0
110	CD4+ T Cells Sustain Aggressive Chronic Lymphocytic Leukemia through a CD40L-Independent Mechanism. Blood, 2019, 134, 683-683.	1.4	0
111	[18f]-(2S,4R)-4-Fluoroglutamine As a New Positron Emission Tomography Tracer in Multiple Myeloma. Blood, 2019, 134, 5542-5542.	1.4	0
112	P-016: The role [18F]-(2S,4R)-4-Fluoroglutamine as a new positron emission tomography tracer in Myeloma in vivo models.. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S47-S48.	0.4	0
113	Development and Validation of [18f](2 <i>S</i> ,4 <i>R</i> )-4-Fluoroglutamine in Multiple Myeloma Mouse Models. Blood, 2021, 138, 2674-2674.	1.4	0
114	Cancer bio-immunotherapy XVII annual NIBIT (Italian Network for Tumor Biotherapy) meeting, October 11-13 2019, Verona, Italy. Cancer Immunology, Immunotherapy, 2021, , 1.	4.2	0
115	Cancer bio-immunotherapy XVIII annual NIBIT-(Italian network for tumor biotherapy) meeting, October 15-16, 2020. Cancer Immunology, Immunotherapy, 2022, , 1.	4.2	0